
The More Protein, the Better?
We're in a protein craze, and it's hard to ignore.
Walk into any grocery store and you'll find rows of protein-fortified energy bars, breakfast cereals, baked goods, snacks, even sports drinks. And on social media, influencers — many with medical or scientific degrees in their bios — claim that most people are woefully deficient.
'Ladies, you're NOT eating enough protein,' Dr. Elie Jarrouge, a doctor in Houston wrote to his nearly 80,000 followers on Instagram in February. Dr. Gabrielle Lyon, another Houston-based physician, said in a recent video on TikTok that the federal recommendations for protein are 'totally wrong.'
One of the most well-known protein proponents is Dr. Peter Attia, a physician, podcaster and author who advises and invests in various protein-related food companies. In his best-selling book, 'Outlive,' he says that the federal recommendations for protein are 'a joke,' suggesting that most healthy and active people should consume nearly three times as much.
In a 2024 survey of 3,000 U.S. adults, 71 percent said they were trying to consume more protein — up from 59 percent in 2022.
So, are the federal recommendations wrong? Would most of us benefit from eating more protein? Or is the obsession just another passing health fad?
The New York Times reviewed dozens of studies and interviewed 12 nutrition scientists, many of whom have been studying protein for decades. All of them agreed that we need more research on the topic, but the science we do have clarifies some of the confusion. Here is a fact-check of six big protein claims we've seen.
The claim: The federal recommendation is wrong.
Nutrition experts in the United States recommend that most healthy adults eat at least 0.8 grams of protein per kilogram of body weight (or 0.36 grams per pound) every day. For a 150-pound adult, this translates to 54 grams per day — or the amount in an 8.5-ounce chicken breast.
Some studies, which Dr. Attia and Dr. Lyon have cited, suggest this amount should be higher — by about 25 to 50 percent, or 1 to 1.2 grams per kilogram of body weight. But scientists don't agree that those studies are better than the ones used to make the federal recommendation.
The best (if limited) evidence we have suggests that the current level is adequate for most people's basic needs, said Wayne W. Campbell, a professor of nutrition science at Purdue University.
The federal recommendation was intended to prevent protein deficiency and to maintain lean tissues, like muscle, in most people, Dr. Campbell added. That level is not necessarily optimal for everyone. Many people — including those who are strength training or losing weight — may benefit from consuming more, he said. (Dr. Campbell, like many of the experts we spoke with, has received research funding from food industry groups. This is common among protein scientists because there is little federal funding for these types of studies.)
Dr. Attia declined multiple requests for comment. In an interview, Dr. Lyon criticized the recommendation, in part because she said it was based only on data from 25-year-old men. That's not true; it was based on data from men and women ages 18 to 99.
The claim: Most Americans aren't getting enough protein.
According to the latest data, the average man in the United States is overshooting the federal protein recommendation by more than 55 percent and the average woman by more than 35 percent.
If most people weren't consuming enough protein, there would be widespread signs of malnutrition, and there are not, said Nancy Rodriguez, a professor emerita of nutritional sciences at the University of Connecticut.
People who follow a balanced diet, like one recommended by the Dietary Guidelines for Americans, are probably 'getting plenty of protein,' Dr. Campbell added — even vegetarians.
That said, not everyone follows a balanced diet, and some people get less than what is recommended, which could put them at risk for deficiency. Teen girls, women and older adults, for instance, are particularly at risk of falling short of the federal recommendation.
Teen girls and women are more likely to restrict their eating, Dr. Rodriguez said, and women tend to consume less meat than men. Older adults also usually eat less overall and may struggle to afford, cook or chew protein-rich foods, she added.
Protein deficiency isn't a widespread problem, experts said. But people in these groups may need to be more attuned to how much they're getting.
The claim: You need more protein to build muscle.
Stacy Sims, an exercise physiologist and nutrition scientist who offers advice to active women online, recommends consuming up to triple the federal recommendation. Dr. Attia, Dr. Lyon and other protein proponents suggest similar targets, along with exercise.
If you're strength training, experts said that you'll probably want to consume more protein than the federal recommendation. But tripling it 'is far more than most people require,' said Luc van Loon, a professor of physiology of exercise and nutrition at Maastricht University in the Netherlands.
In one well-designed trial of 50 middle-aged participants who followed a rigorous strength training program for 10 weeks, half consumed about 1.5 times the federal recommendation and the other half consumed about twice as much. After the training period, both groups were stronger and had gained lean mass, with no difference in results between them.
For most people who want to build muscle, consuming around 1.5 to two times the federal recommendation is plenty, said David Church, an assistant professor of geriatrics at the University of Arkansas for Medical Sciences. Beyond that amount, he added, the effects of protein on muscle gain 'kind of plateaus.'
Some small studies, Dr. Church said, do suggest that certain athletes — like those doing rigorous strength and endurance training, or those recovering from injuries or restricting their calories — may benefit from consuming up to three times the federal recommendation. But more research is needed, and these scenarios don't apply to most people, he added.
In an email, Dr. Sims emphasized that her recommendations were mainly for serious female athletes who are typically training for a specific sport or competition.
The claim: Older adults need more protein.
There is some evidence that consuming more protein as you get older can reduce the risk of age-related muscle loss, but these findings have been mixed.
In a three-year study of nearly 25,000 women ages 65 to 79, for example, those who consumed about 50 percent more protein than the federal recommendation were less frail than those who consumed less.
But other studies in older adults, including randomized controlled trials, have not consistently shown a benefit to consuming more protein. In a trial published in 2018, researchers provided 92 older men with diets that either matched the federal recommendation or contained 63 percent more protein. After six months, the researchers found no differences in lean mass, muscle strength, walking speed, fatigue or well-being between groups.
Despite the mixed evidence, nutrition experts in Europe encourage all people over 65 to consume at least 25 percent more protein than the U.S. guidelines recommend. And, they add, older people may benefit from eating even more if they are healing from injury or recovering from surgery or hospitalization — a recommendation Dr. van Loon agreed with.
The claim: High protein diets can help with weight loss.
Many posts on social media — many of them geared toward women — promote high protein diets for weight loss.
Some short-term trials in women and men have shown that eating 1.5 to two times the federal recommendation helped people lose more weight than lower protein diets did. Research also suggests that protein can reduce hunger hormone levels and be more satiating than carbohydrates or fats.
But longer-term studies haven't always found that people lose more weight on high-protein diets compared with other weight loss diets, said Bettina Mittendorfer, a professor of nutrition and exercise physiology at the University of Missouri School of Medicine.
Still, research suggests that if you're actively trying to lose weight, increasing your protein may help you lose more fat mass and retain more lean mass, which includes muscle. In a review published in 2024, scientists concluded that consuming at least 25 percent more protein than the recommended amount may help preserve muscle during weight loss.
For people consuming fewer calories, whether because they are dieting or taking a medication like Wegovy or Ozempic, it's important to get adequate protein, Dr. van Loon said. Strength training at least twice a week is also key to preserving muscle during weight loss, he added.
The claim: The more protein the better.
If you spend time online, you may see posts urging you to eat significantly more protein and that there's no harm in doing so.
But focusing too much on protein can come with some downsides, experts said. It might, for example, leave less room for other healthy foods, like fruits, vegetables and whole grains — which most of us need more of, Dr. Church said.
It could also prompt you to eat more animal products, which are linked to higher risks of cardiovascular disease and earlier death, said Dr. Frank B. Hu, a professor of nutrition and epidemiology at the Harvard T.H. Chan School of Public Health. Or, you might rely on processed sources of protein, like powders or bars, instead of whole food sources of protein like beans, tofu, nuts, whole grains, fish or chicken, which are more healthful options, he said.
Too much protein may also strain the kidneys in those with chronic kidney disease, Dr. Campbell said. More than one in seven adults in the United States are estimated to have chronic kidney disease, and up to nine out of 10 don't know that they have it.
'That gives me pause about the more-is-better approach,' Dr. Campbell said.
Dr. Mittendorfer sees echoes of past nutrition trends in today's protein craze. 'There are these waves in public opinion,' she said. Fats and carbohydrates were once villainized, yet scientists found that the nutrients themselves weren't bad; the issue was more about overeating certain foods they were in.
As with any nutrient, she added, you shouldn't have too much or too little. There's a 'Goldilocks zone' that meets your body's needs without causing problems, she said. The same is true for protein.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
8 minutes ago
- Associated Press
Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations
CEDAR PARK, Texas, June 11, 2025 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical, a privately held biomedical device company, today announced the issuance of new patents in the United States and European Union for its advanced drug delivery technologies. The patents, titled 'Cartridge Devices for Administration of a Medicament' (U.S. Patent No. 12329949) and 'Hand-Operated Devices for Administration of a Medicament' (EU Patent No. 3946526), further strengthen Zeteo's ZTech™ delivery platform portfolio for the administration of drugs and biologics via nasal, ophthalmic, and sublingual routes. These patented innovations advance Zeteo's ZTech-L™ and ZTech-P™ delivery systems, which include both single-use disposable and multi-dose, cartridge-reloadable handheld devices. The platforms support the administration of therapeutics in both liquid and dry powder formulations, including vaccines, biologics, and specialty drugs. Nasal delivery, in particular, is emerging as a highly effective, non-invasive alternative for treating conditions such as pain, emesis, seizures, neurodegenerative and autoimmune disorders, infectious diseases, and bioterror threats. 'We are seeing increasing global demand for metered-dose nasal, ophthalmic, and sublingual delivery devices that are compact, intuitive, and suitable for self-administration,' said Timothy Sullivan, CEO of Zeteo Biomedical. 'A unique feature that sets our device technology apart is its ability to function reliably in any physical orientation, making it ideal for medication delivery in both terrestrial and space-based microgravity environments. This capability opens exciting new frontiers for Zeteo including applications in space-based healthcare.' Zeteo's integrated delivery platforms and technical services streamline the development and commercial-scale production of patient-centric drug/device combination products for pharmaceutical and biotech partners. This focus on patient-friendly design improves treatment adherence and medical outcomes, while enhancing product differentiation and brand value for manufacturers. Zeteo's platform technologies are designed to meet the evolving demands of global and interstellar healthcare markets, delivering precision, performance, and portability for the next-generation of therapeutic drug/device combination products. About Zeteo Biomedical LLC Zeteo Biomedical is a Texas-based medical device company focused on the development and commercialization of advanced drug and biologic delivery systems. The company specializes in intranasal, ophthalmic, and sublingual delivery technologies designed to improve patient outcomes through precision dosing, portability, and ease of use. Zeteo's proprietary platforms are supported by an extensive patent portfolio and a range of product development services tailored to accelerate time to market for pharmaceutical and biotech clients worldwide. To learn more, visit MEDIA CONTACT: Cathy Diehl Zeteo Biomedical LLC +(1) 512-614-0144 [email protected] *LOGO link for media: NEWS SOURCE: Zeteo Biomedical LLC Keywords: Biotechnology, Zeteo Biomedical, drug delivery, vaccines, med tech, pharmaceuticals, biotech, public health, Nasal and Ophthalmic Drug Delivery Device, CEO Timothy Sullivan, CEDAR PARK, Texas This press release was issued on behalf of the news source (Zeteo Biomedical LLC) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P126872 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Yahoo
18 minutes ago
- Yahoo
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER
The clinical trial at Linkoping University will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, June 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the Swedish Ethical Review Authority and the Swedish Medical Products Agency have authorized a double-blind phase 2 clinical trial studying its botanical psilocybin drug candidate, PEX010, at Linkoping University. The trial will be the first to study the effects of psilocybin in the treatment of prolonged grief disorder. "In an aging society where people may outlive their family members by decades, it is crucial to develop treatment options for those with prolonged grief disorder," said Dr. Rebecca Böhme, Associate Professor at the Linkoping Center for Social and Affective Neuroscience. "This trial will assess whether psilocybin can improve adaptation to the loss experience. We are grateful to Filament Health for facilitating this research." People with prolonged grief disorder are at a 20 percent increased mortality risk. Previous psychological research suggests that the loss of a close person affects self-identity, an aspect of the higher cognitive self. Psilocybin is suggested to cause a transient shift from reliance on prior experiences towards current sensations. The clinical trial at Linkoping University will utilize this shift combined with a self-touch intervention to support re-learning about the bodily self in a trial population of 120 individuals. "We're pleased to provide PEX010 to Linkoping University for this much-needed area of research," said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. "This will be the ninth European clinical trial to study our drug candidate, positioning Filament as the region's leading supplier of GMP psilocybin." The trial at Linkoping University is expected to begin dosing in Q3 2025. PEX010 is authorized for investigation in 52 clinical trials worldwide for 14 mental health indications. ABOUT FILAMENT HEALTH (OTC:FLHLF)Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at and on Twitter, Instagram, and LinkedIn. FORWARD LOOKING INFORMATIONCertain statements and information contained in this press release and the documents referred to herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws. SOURCE Filament Health Corp. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Cuts to Medicaid for Ohioans with disabilities could take away home care and job help
(iStock / Getty Images Plus) As the Ohio Senate moves forward with its budget proposal, advocates for Medicaid are hoping changes can be made to avoid significant impacts to low income residents, elderly Ohioans, and people with disabilities. Funding from Medicaid allows 3 million Ohioans access to health care services, including more than 770,000 who receive them through the Medicaid expansion program instituted in 2014. That expansion program allows people who weren't eligible for the traditional Medicaid programs but were still in categories of need to access health care. The existence of that program dropped the uninsured rate in Ohio to historic levels, according to the Health Policy Institute of Ohio. Along with health care, Medicaid dollars help with services that aren't necessarily connected to medical treatment, like home care, employment help, transportation, and a direct care provider who helps with all of those things. 'In many cases, if there wasn't Medicaid dollars behind it, I know of many people whose ability to live outside of a hospital or in the community would be threatened,' said Jules Patalita, a disability rights advocate for Sylvania-based The Ability Center. So advocates were disappointed to see the Ohio Senate maintain a provision from both the Ohio House's and Gov. Mike DeWine's budget proposals that would eliminate the Medicaid expansion group if the federal government reduces their level of support (currently at 90%) by even 1%. 'This would be a substantial loss for many working Ohioans,' said Kathryn Poe, researcher for the think tank Policy Matters Ohio. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX Also included in the Senate's budget proposal is the elimination of a Medicaid waiver that 'would have provided continuous coverage for kids up to age 3,' Poe said, and a separate section of the budget that would 'allow the state to pause, eliminate or change other funds related to all other federal grants, should Congress adjust or eliminate funding for that program.' Poe did praise the Senate proposal for removing a House-submitted provision limiting Medicaid reimbursement for doulas to only six Ohio counties. 'This will ensure that Ohio parents continue to have access to culturally appropriate birthing resources and management,' Poe said. Concerns about loss of access don't just extend to physical health concerns or daily home services, but also to behavioral health services, on which 47% of Ohio adults on Medicaid rely, according to Kerstin Sjoberg, president and CEO of Disability Rights Ohio. 'If you don't have access to some sort of insurance like Medicaid, it's going to be almost impossible to get those services,' Sjoberg said. The state-level discussions come as federal budget reconciliation also touches on Medicaid funding as the Trump administration and Republicans in Congress attempt to slash federal spending by $880 billion over the next decade, particularly from public assistance programs like the Supplemental Nutrition Assistance Program (SNAP) and Medicaid. U.S. House Speaker Mike Johnson and other leaders have talked about 'abuse' or 'fraud' as sources of revenue loss for the country in public programs, something those who engage with users of programs like Medicaid push back on. 'In reality, Medicaid is one of the most cost-effective and widely used safety nets in the country,' said the advocacy group Innovation Ohio in a call-to-action email over the congressional budget proposals. 'If this bill becomes law, the result will be fewer people with health care, more families pushed into poverty and deeper inequality. Rural hospitals could shut down.' According to a study by the Commonwealth Fund, Ohio could be one of the hardest hit economies if Medicaid cuts at the federal level come to fruition, cuts that could mean 29% more Medicaid spending by states or cuts to other programs, like education, to offset the Medicaid losses. One thing that will have to be addressed whether or not the cuts are realized in the state and federal budgets is the workforce that helps those who use Medicaid for home care and other services. Patalita said the word 'crisis' has been used in talking about the shortage of direct care providers, similar to the shortage of child care workers needed to provide adequate access to that service. 'We've talked to people who have had to wait weeks to be able to receive services in the home, because there just aren't enough providers out there,' Patalita said. The Ability Center did a study after the previous state budget increased the reimbursement rate for direct care providers under the state Medicaid program. That study showed that while reimbursements rates and, for that matter, provider wages should go up, the solution to the shortage problem wouldn't come with just one answer. 'The direct care crisis is too complex of an issue for a single action to remedy,' The Ability Center found. The study identified three 'major elements' of the shortage: high turnover rates, low hourly wages (lower than 'many entry level positions in retail and food service,' according to the study), and a lack of consistency in benefits. 'This failure by agencies to provide benefits adds to the worker shortage and forces those requiring home care to carry the burden of decreased access to care, especially those in rural areas,' the study found. Eliminating Medicaid funding, including the expansion group, will make life harder for those Ohioans who need the services, Sjoberg said, 'but it will also make it necessary that the direct care workforce is supported in other ways.' SUPPORT: YOU MAKE OUR WORK POSSIBLE